Clinical Trial Update: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating long-acting cabotegravir in combination with the monoclonal antibody VRC07-523LS for maintaining viral suppression in adults with HIV-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC-HIVMAB075-00-AB (VRC07-523LS) (VRC07-523LS)
• cabotegravir (cabotegravir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2025-05-23